Skip to main content Skip to section navigation Skip to footer
Trevena, Inc. Corporate Home
  • About
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYK® (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Governance Documents

Trevena, Inc. Appoints Marvin H. Johnson, Jr. to Board of Directors

Mar 18, 2021 7:00 am EDT

Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results

Mar 9, 2021 7:00 am EST

Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Mar 5, 2021 7:00 am EST

Trevena, Inc. to Participate in March Virtual Investor Conferences

Mar 1, 2021 7:00 am EST

Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Feb 22, 2021 7:00 am EST

Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy

Jan 28, 2021 7:00 am EST

Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences

Jan 7, 2021 7:00 am EST

Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts

Jan 6, 2021 7:00 am EST

Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting

Dec 10, 2020 8:43 am EST

Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy

Nov 20, 2020 7:00 am EST
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Sitemap
©2025 Trevena, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Terms of Use
  • Sitemap
  • Accessibility Statement